Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy
Status:
Completed
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
The study will evaluate the incidence of major bleeding (including clinically relevant
non-major (CRNM) bleeding) events in women undergoing surgery for gynecologic cancer with
apixaban 2.5 mg twice a day (BID) compared to current standard of care, subcutaneous
enoxaparin 40 mg once a day (QD) for 28 days post surgery.